Ann: Imugene AGM Presentation, page-82

Back to what you can expect:

They now consider to accept a full t/o - first box!!!!! in the presentation.

Hopper "confessed" that US investors need more data - reasonable and general practice, but how in the world can ALA manage such a high MC when not even getting an IND from the FDA? Are their iNKT pre-clinicals really worth that much and if yes, what does it say about IMU's assets.

Her-Vaxx got mentioned by PH but not included in LC's answer. PD1-Vaxx now trialed in London for about 12 months and clearly, if there was an extraordinary result we would have heard from them by now. If really competitive to Keytruda, we would know by now.

I trusted them when it comes to trial speed progress and FDA feedback. Getting all green lights from the FDA is necessary for any approvals but is no guarantee for any deals. That, I have to confess, has been one of my mistakes thinking FDA - ticked automatically means $$$$$ - ticked.

His comments related to competition is in line with comments from current / previous CHM CEOs, autologous CD19 heavily overcrowded, allogeneic still wide open. But exactly that is what should have already brought in offers from those trying to leap to the front lines. The ph1 / 1b data so far are great according to IMU, why hasn't any big pharma wanted Azer-Cel from Precision a year ago or why isn't anyone jumping on to it right now?

Is it the same Her-Vaxx mistake IMU is repeating again, waiting for an offer that's unrealistic and missing out by refusing a reasonable offer?

I sold out at CHM and IMU because I have doubts that the assets are that competitive and the way Hopper talked about the likelihood of deals confirmed that IMU either isn't ready yet or the market isn't just interested at all. Regardless of what quality product one wants to sell, if unwanted, even the best product can't be sold. And I got the feeling that this is the case here and at CHM. This is my opinion only and I could be totally wrong with my conclusions but as long as US funds and big pharma stay away from IMU and CHM I will do the same.

I am holding RAD as the control has shifted away from Hopper to Lantheus and US funds. Have to admit, it hasn't protected the sp but at least funding is secured and the sell down has been caused by a forced seller, a 4c - CR participant.

GLTA